Related Experiment Videos
[Cell therapy in renal cell carcinoma]
1Service de cancérologie, hôpital Saint-André, CHU, 1, rue Jean Burguet, 33075 Bordeaux, France. alain.ravaud@chu-bordeaux.fr
Bulletin Du Cancer
|November 12, 2003
Summary
Cellular therapy, including dendritic cells and stem cell transplantation, is crucial for treating renal cell carcinoma due to its responsiveness to immunotherapy. Earlier methods like Lymphokine Activated Killer (LAK) and Tumor Infiltrating Lymphocytes (TIL) paved the way for current advancements.
Area of Science:
- Oncology
- Immunology
- Cellular Therapy
Context:
- Renal cell carcinoma (RCC) exhibits significant sensitivity to immunotherapy.
- Cellular therapy represents a key component in RCC treatment strategies.
- Historical cellular therapies for RCC include Lymphokine Activated Killer (LAK) cells and Tumor Infiltrating Lymphocytes (TIL).
Purpose:
- To review the role and evolution of cellular therapy in the context of renal cell carcinoma treatment.
- To highlight current clinical evaluations focusing on advanced cellular therapy modalities.
Summary:
- The integration of cellular therapy into renal cell carcinoma (RCC) management is essential, leveraging RCC's known immunotherapeutic sensitivity.
- While LAK and TIL cells represent earlier cellular therapy approaches, current clinical focus is on dendritic cells and allogeneic blood stem cell transplantation.
- These advanced methods are central to ongoing major clinical evaluations for RCC.
Impact:
- Establishes cellular therapy as a vital strategy in renal cell carcinoma treatment.
- Underscores the shift towards more sophisticated cellular therapies like dendritic cells and stem cell transplantation.
- Provides a concise overview of the evolving landscape of cellular therapy for kidney cancer.